key: cord-0960584-t6vspwdx
authors: Desai, Amar D.; Boursiquot, Brian C.; Moore, Catherine J.; Gopinathannair, Rakesh; Waase, Marc P.; Rubin, Geoffrey A.; Wan, Elaine Y.
title: Autonomic dysfunction post-acute COVID-19 infection
date: 2021-11-27
journal: HeartRhythm Case Rep
DOI: 10.1016/j.hrcr.2021.11.019
sha: 209b9ba8e2126dce1a93067f64234cfb901a3bdf
doc_id: 960584
cord_uid: t6vspwdx

nan

SARS-CoV-2 infection which causes the disease COVID-19 is most known for its 32 severe respiratory complications. However, a variety of extrapulmonary effects 33 have since been described, with cardiovascular complications being amongst the 34 most common [1] . Those who recover from the acute phase of COVID-19 may be 35 left with residual symptoms such as chest pain and dyspnea, resulting in a 36 decreased quality of life and a syndrome sometimes described as "long 37 COVID" [2] . Recent evidence suggests that survivors with some of these chronic 38 symptoms may have autonomic dysfunction with features of postural orthostatic 39 tachycardia syndrome (POTS) and/or inappropriate sinus tachycardia (IST) [3, 4] . 40 POTS is characterized by symptoms that occur with standing, an increase in 41 heart rate of ≥30 beats per minute (or heart rate >120 bpm) when moving from a 42 supine to a standing position, and the absence of orthostatic hypotension [5] . IST 43 is defined as a sinus heart rate >100 beats per minute at rest without an 44 identifiable cause of sinus tachycardia [6] . Cardiac manifestations of autonomic 45 dysfunction lie on a wide spectrum and can therefore be classified as either 46 POTS, IST, or other unspecified symptoms such as tachycardia and palpitations 47 without a clear, single underlying pathological mechanism. [7] The treatment of 48 these arrhythmias includes nonpharmacologic management, such as increasing 49 salt and fluid intake, as well as the use of oral medications. Beta-blockers or off 50 label use of ivabradine have used reported to be used in both syndromes with 51 the goal of controlling heart rate to reduce the symptoms [8, 9] . Other therapies 52 alpha-2 agonists [8] . 54

There is a need to understand the patient characteristics and risk factors for 56 developing AD as a sequela of COVID-19. Furthermore, there is limited 57 management information specific to patients suffering from AD following COVID-58 CoV-2 antibodies on serologic testing. The date of COVID-19 diagnosis was 75 J o u r n a l P r e -p r o o f defined as the date of positive PCR testing, or when unavailable, the date of 76 initial symptom onset. Baseline symptoms were obtained from a combination of 77 chart review and self-report via a phone-administered survey to which patients 78

consented. We collected diagnostic information from laboratory reports as well as 79 reports of any available imaging, including computed tomography (CT) scans, 80 cardiac magnetic resonance imaging (MRI), and echocardiograms. Information 81 on prescribed treatments was obtained from chart review, whereas data 82 regarding symptomatic improvement following initiation of these treatments were 83 obtained from the survey mentioned above. increasing salt intake. Of these medications, beta-blockers were the most 114 common, with five patients (55.6%) being prescribed beta-blockers. Three 115 patients were prescribed metoprolol succinate, and two patients were prescribed 116 metoprolol tartrate. Two of these patients had intolerance to metoprolol, in one 117 case resulting in a switch to pindolol, and in another case resulting in a switch to 118 ivabradine. Of the remaining patients prescribed medications, one was 119 prescribed midodrine, one was prescribed colchicine, and two were prescribed 120

Upon follow-up phone survey of included patients (Table 2) COVID-19 autonomic dysfunction [3, 4, 10, 11] . 146

Of patients prescribed medications, a majority received beta-blockers, which 148

improved symptoms in 4 out of 5 patients. Anti-inflammatory medications were 149 the second most common types of treatment and resulted in symptom 150 improvement in 2 out of 3 cases. However, it is important to note that among 151 patients who received medications, a majority still had ongoing symptoms at 152 follow-up without complete resolution. This is consistent with a case series by 153

remained symptomatic despite pharmacologic management [4] . Similarly, in 155

Blitshteyn and Whitelaw's study on post-COVID AD [10] , a vast majority of patients 156 received medications, but 85% of the cohort had residual symptoms months 157 greater than 6 months after initial COVID-19 diagnosis. These findings suggest 158 that while these medications, especially beta-blockers, certainly may improve 159 symptoms of patients, post-COVID AD is consistent with the general prognosis of 160 IST and POTS, which are both challenging to manage and often require ongoing 161 management to reduce symptoms [6, 12] . Further larger studies investigating the 162 predominant presenting symptoms of patients and which medications they 163 respond to may help improve our management. 164

Beyond receipt of medication, of six patients receiving the COVID-19 vaccine, 166 three patients noticed improved symptoms and three symptoms noticed 167 unchanged symptoms. Importantly, none of these patients experienced 168

worsening of symptoms, a complication which was originally suspected and 169 feared for patients both with long COVID and previous COVID-infection during 170 initial vaccine rollout [13] . This small cohort suggests the feasibility of vaccination in 171 the population of patients suffering from suspected post-COVID AD, with no 172 specific worsening of symptoms noted. A study of 6,030 individuals in the UK 173 revealed the odds of long COVID symptoms, including autonomic dysfunction, 174

were nearly halved when receiving both doses of the SARS-CoV-2 vaccine, 175 supporting our findings. [14] While the exact mechanism for why these symptoms 176 are alleviate following immunization remain unclear, among many hypotheses, 177 one which may be likely is that residual viral particles in tissues may be 178 ambulatory monitoring further as a means of confirming a suspected diagnosis of 208 autonomic dysfunction. Our study also lacked serial routine testing for markers of 209 inflammation or autoimmunity, which prevent us from making comparisons to 210 other cohorts or testing the observation that POTs patients may have underlying 211 autoimmune disease [4, 15] . One third of Blitshteyn's cohort had laboratory testing 212 consistent with inflammation or autoimmunity, but a significant minority of 213 patients in this cohort also had pre-existing autonomic symptoms even prior to 214 COVID-19, so they may represent a different population than ours [10] . 

Beta-blocker 5/9 (55.6%) Midodrine 1/9 (11.1%) Anti-inflammatory 3/9 (33.3%) After receiving meds, symptoms ______: Resolved 2/9 (22.2%) Improved 4/9 (44.4%) Unchanged 3/9 (33.3%) Worsened 0/9 (0.0%)

Vaccinated 6 (54.5%) Unvaccinated 0 (0.0%) Unknown 5 (45.5%) Number of doses received One 0 (0.0%) Two 6/6 (100.0%) Vaccine Received Pfizer 4/6 (66.7%) Moderna 1/6 (16.7%) Unknown 1/6 (16.7%) After vaccination, symptoms _________: Resolved 1/6 (16.7%) Improved 2/6 (33.3%) Unchanged 3 (50.0%) Worse 0 (0.0%) J o u r n a l P r e -p r o o f

Extrapulmonary manifestations of 245 COVID-19

Post-acute COVID-19 syndrome

Autonomic dysfunction 249 following COVID-19 infection: an early experience

Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia 253 Syndrome: The Swedish Experience

Postural orthostatic tachycardia 255 syndrome

Inappropriate sinus tachycardia

Clinical approach to autonomic dysfunction

heart rhythm society 261 expert consensus statement on the diagnosis and treatment of postural 262 tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. 263 Heart Rhythm

Arrhythmias Associated with COVID-19

Postural orthostatic tachycardia syndrome 267 (POTS) and other autonomic disorders after COVID-19 infection: a case series of 268 20 patients

Natural history and clinical 270 outcomes of inappropriate sinus tachycardia

Previous COVID-275 19 infection, but not Long-COVID, is associated with increased adverse events 276 following BNT162b2/Pfizer vaccination

Risk factors and disease profile of 278 post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom 279 Study app: a prospective, community-based, nested, case-control study

The possible association between COVID-19 and postural 282 tachycardia syndrome